Daewoong Pharma (069620) - Total Liabilities
Based on the latest financial reports, Daewoong Pharma (069620) has total liabilities worth ₩1.26 Trillion KRW (≈ $851.43 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 069620 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Daewoong Pharma - Total Liabilities Trend (2007–2024)
This chart illustrates how Daewoong Pharma's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Daewoong Pharma.
Daewoong Pharma Competitors by Total Liabilities
The table below lists competitors of Daewoong Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FARO Technologies Inc
NASDAQ:FARO
|
USA | $234.86 Million |
|
Ningbo Cixing
SHE:300307
|
China | CN¥1.19 Billion |
|
Himalaya Shipping Ltd
OL:HSHP
|
Norway | Nkr705.20 Million |
|
Eit Environmental Development Group
SHE:300815
|
China | CN¥5.45 Billion |
|
Surge Energy Inc.
TO:SGY
|
Canada | CA$629.44 Million |
|
Multi Bintang Indonesia Tbk
JK:MLBI
|
Indonesia | Rp2.01 Trillion |
|
Truking Technology Ltd
SHE:300358
|
China | CN¥8.66 Billion |
|
Shenzhen Tianyuan Dic Info Tech
SHE:300047
|
China | CN¥4.04 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Daewoong Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Daewoong Pharma to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daewoong Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daewoong Pharma (2007–2024)
The table below shows the annual total liabilities of Daewoong Pharma from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩1.05 Trillion ≈ $711.56 Million |
+37.65% |
| 2023-12-31 | ₩762.77 Billion ≈ $516.92 Million |
-7.22% |
| 2022-12-31 | ₩822.12 Billion ≈ $557.14 Million |
+15.34% |
| 2021-12-31 | ₩712.77 Billion ≈ $483.04 Million |
+6.12% |
| 2020-12-31 | ₩671.66 Billion ≈ $455.17 Million |
+10.15% |
| 2019-12-31 | ₩609.75 Billion ≈ $413.22 Million |
+1.62% |
| 2018-12-31 | ₩600.04 Billion ≈ $406.64 Million |
+3.10% |
| 2017-12-31 | ₩581.99 Billion ≈ $394.40 Million |
+7.75% |
| 2016-12-31 | ₩540.15 Billion ≈ $366.05 Million |
+48.28% |
| 2015-12-31 | ₩364.29 Billion ≈ $246.87 Million |
+52.58% |
| 2014-12-31 | ₩238.76 Billion ≈ $161.80 Million |
+69.27% |
| 2013-12-31 | ₩141.05 Billion ≈ $95.59 Million |
+47.30% |
| 2012-12-31 | ₩95.76 Billion ≈ $64.89 Million |
-29.61% |
| 2011-12-31 | ₩136.04 Billion ≈ $92.20 Million |
-34.40% |
| 2008-12-31 | ₩207.39 Billion ≈ $140.55 Million |
+68.28% |
| 2007-12-31 | ₩123.24 Billion ≈ $83.52 Million |
-- |
About Daewoong Pharma
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplem… Read more